Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/08/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 04/08/22 | 8-K | Current report filing |
|
   |
3 |
| 03/29/22 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
23 | |
| 03/16/22 | 8-K | Current report filing |
|
|
2 |
| 02/08/22 | 8-K | Current report filing |
|
|
4 |
| 02/08/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
19 |
| 02/03/22 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
4 | |
| 12/17/21 | 8-K | Current report filing |
|
|
5 |
| 12/17/21 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
82 |
| 10/07/21 | 8-K | Current report filing |
|
|
2 |
